Company Insights

PCRX supplier relationships

Explore interactive graphBrowse insights index
PCRX supplier relationship map

Pacira BioSciences (PCRX): supplier map and what it means for investors

Pacira BioSciences sells non‑opioid pain‑management and regenerative‑health products (notably EXPAREL, ZILRETTA and iovera). The company monetizes through product sales, recurring unit‑based manufacturing arrangements and selective licensing that expands its pipeline — a mix that ties revenue growth directly to a small set of manufacturing partners and occasional licensing spend on R&D. Investors should value Pacira not only as an end‑market product company but also as an operator whose gross margins and production continuity are materially exposed to a handful of contract manufacturers and strategic licensors. For deeper supplier risk profiles visit https://nullexposure.com/.

The supplier roster in plain English

Below are the active supplier and partner relationships disclosed in regulatory and market commentary, summarized for business‑minded readers.

Patheon UK Limited — long‑form manufacturing and technical transfers

Pacira’s FY2024 10‑K discloses multiple, standing agreements with Patheon UK Limited: a Manufacturing and Supply Agreement (originally dated July 31, 2015), a May 1, 2018 Technical Transfer and Service Agreement, and a Side Letter executed June 5, 2023, underscoring an ongoing manufacturing and technical‑transfer relationship. (Source: Pacira FY2024 10‑K filing.)

AmacaThera, Inc. — in‑licensing counterparty for a clinical asset

Pacira disclosed in its Q4/2025 results that R&D expense in the quarter included a $5.0 million upfront payment to AmacaThera for the in‑licensing of PCRX‑2002 (formerly AMT‑143), signaling active pipeline augmentation via external licensing. (Source: Pacira press release reporting fourth quarter and full‑year 2025 results, Feb 26, 2026; also reported in market coverage around the same release.)

Thermo Fisher Scientific — dedicated manufacturing suites in the U.K.

Pacira’s filings state that EXPAREL and ZILRETTA are manufactured at Thermo Fisher’s Swindon, U.K. facility under strategic co‑production, manufacturing and technical‑transfer agreements; Thermo Fisher completed technical transfer activities and fitted dedicated manufacturing suites for Pacira product lines. (Source: Pacira FY2024 10‑K filing.)

Carlisle (Carlisle Companies, Inc.) — contract manufacturer for iovera Smart Tips

Pacira entered a Manufacturing and Supply Agreement with Carlisle in January 2020 to make iovera Smart Tips at Carlisle’s Tijuana, Mexico facility; since April 2022 Carlisle has produced all iovera Smart Tips and Pacira pays fees based on units delivered. (Source: Pacira FY2024 10‑K filing.)

Why these relationships matter — operating model and commercial constraints

Pacira’s supplier topology creates clear operating characteristics that matter for valuation and operational risk.

  • Contracting posture: long‑duration, committed manufacturing relationships. Pacira discloses long‑term manufacturing agreements and multi‑year minimum commitments (the company reports roughly $59.9 million of minimum, non‑cancelable contractual commitments for contract manufacturing services as of Dec 31, 2024, with scheduled amounts through 2028). These commitments create predictable capacity and cost baselines but also fixed outflows if demand softens. (Source: Pacira FY2024 10‑K filing.)

  • Concentration and criticality: a small number of approved sites. Pacira states that specific facilities are the only currently approved global sites for manufacturing EXPAREL, ZILRETTA and iovera products; that implies single‑site or small‑cluster single‑source risk for critical product lines. (Source: Pacira FY2024 10‑K filing.)

  • Geographic exposure: meaningful EMEA manufacturing footprint. Technical transfer and construction at Thermo Fisher’s Swindon facility establish an EMEA manufacturing node that is material to EXPAREL/ZILRETTA supply chains. Investors should treat cross‑border logistics and regulatory inspections as potential drivers of volatility. (Source: Pacira FY2024 10‑K filing.)

  • Relationship maturity and enforceability: multi‑year start dates with extensions. Several agreements date back to 2014–2015 (Thermo Fisher/EXPAREL arrangements) and 2020 (Carlisle), with contractual language supporting multi‑year terms and automatic extensions in some cases — a sign of an operational model built on durable third‑party manufacturing partnerships. The Carlisle Agreement explicitly includes an initial five‑year term with automatic one‑year renewals unless terminated in writing, which reinforces continuity for iovera Smart Tip supply. (Source: Pacira FY2024 10‑K filing.)

  • Service and third‑party dependence beyond manufacturing. Pacira also outsources customer service, distribution, IT and finance‑adjacent functions to third‑party providers, creating multiple touchpoints where operational control is partially ceded. (Source: Pacira FY2024 10‑K filing.)

For an investor‑grade supplier risk summary and tailored exposure dashboard, see https://nullexposure.com/.

Investment implications: where upside and risk concentrate

  • Upside drivers: durable manufacturing agreements reduce capex needs and enable scalable gross margin capture as product volumes increase; targeted licensing (for example, the PCRX‑2002 deal with AmacaThera) can accelerate pipeline value with limited upfront capital. (Source: Pacira FY2024 10‑K; Feb 26, 2026 earnings release.)

  • Primary risks: supply concentration at a few approved sites, contract termination windows and minimum purchase commitments that can pressure cash flow if sales decline, and regulatory or inspection disruptions in key geographies (e.g., Swindon, U.K. and Tijuana, Mexico). These are operational risks that translate directly into revenue continuity and margin volatility. (Source: Pacira FY2024 10‑K filing.)

  • Near‑term watch items: execution of PCRX‑2002 development milestones (following the $5M upfront), any announcements of new manufacturing qualifications or geographic diversification, and contractual renegotiations or capacity expansions with Thermo Fisher, Carlisle or Patheon. (Source: Pacira FY2024 10‑K; Pacira Q4/2025 press release.)

Quick checklist for due diligence

  • Confirm the approved manufacturing sites for each product and any contingency or redundancy plans.
  • Monitor contract expiry and renewal mechanics for Thermo Fisher and Carlisle arrangements and the cadence of non‑cancelable manufacturing commitments.
  • Track pipeline licensing spend and milestone schedules (e.g., PCRX‑2002 and counterparties like AmacaThera) as a signal of future R&D outlays and product expansion.

For a detailed supplier risk profile and to monitor contract expirations and commitments in one place, visit https://nullexposure.com/.

Bottom line for operators and investors

Pacira’s business model is product‑driven but execution depends on a narrow set of manufacturing partners and selective licensing deals. That structural reality compresses both risk and optionality: when production partners perform, Pacira benefits from scale without heavy capex; when a partner faces disruption, product revenues are exposed. Active monitoring of contract terms, geographic concentration, and pipeline licensing milestones is essential for any serious investor or operator evaluating PCRX supplier relationships. For ongoing updates and supplier analytics, start at https://nullexposure.com/.